This content is machine translated CAR-T Cells Own immune cell as therapy With the rapid development of new therapeutic options in oncology, immunotherapy has a high priority. Thus, CAR T cells are also a promising approach to treat advanced cancers. In particular,…
View Post 11 min This content is machine translated Sideropenia Iron deficiency in the oncological patient Worldwide, iron deficiency is the most common deficiency disease. In Europe, the prevalence is 5-10% and is one of the most common causes of anemia, accounting for about 50%. An…
View Post 10 min This content is machine translated Rarer tumor entities Current therapeutic options in metastatic renal cell carcinoma. Renal cell carcinoma is one of the rather rare tumor entities. Therefore, treatment options were very limited for years and therapy was difficult. Meanwhile, tyrosine kinase inhibitors have expanded the…
View Post 13 min This content is machine translated Radiogenic pneumonitis Calculable risk with modern radiotherapy Radiation therapy of thoracic tumors, particularly lung carcinoma, is caught between the goals of maximizing tumor control probability and avoiding toxicities. Radiogenic pneumonitis is a relevant side effect. This occurs… CME-Test
View Post 1 min This content is machine translated BRCA-mutated advanced ovarian cancer. PARP inhibitor shows long-term benefit in terms of PFS Ovarian cancer is the eighth leading cause of death among women with cancer worldwide. In Switzerland, approximately 620 patients are newly diagnosed with ovarian cancer each year. Approximately 22% of…
View Post 3 min This content is machine translated Non-small cell lung cancer and other solid tumors In the pipeline: KRAS G12C inhibitor Sotorasib The KRAS gene is one of the most frequently mutated oncogenes in human cancers and thus represents a promising target in the therapy of diverse solid tumors. Sotorasib is currently…
View Post 5 min This content is machine translated Non-small cell lung cancer Many lids for many pots In the treatment of non-small cell lung cancer, an extremely large amount has been achieved in a short time. Keeping track of so many rapid innovations can be quite difficult,…
View Post 3 min This content is machine translated Myeloid diseases New trends in the treatment of acute myeloid leukemia Understanding about myeloid diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), is becoming more concrete thanks to intensive research. Recent study results have shown that there is…
View Post 3 min This content is machine translated Blood-brain barrier When breast cancer invades the brain Patients with breast cancer can develop metastases in the brain – which means an even worse chance of survival. There may be factors in the blood that can predict this…
View Post 2 min This content is machine translated Non-small cell lung cancer Focus on current therapy management of NSCLC Non-small cell lung cancer is a common cancer with generally poor prognosis. Scientific advances have led to new forms of therapy increasing the chance of survival. In particular, the development…
View Post 4 min This content is machine translated Immunotherapy A narrow ridge With the rapid development of new, highly efficient anticancer drugs such as checkpoint inhibitors, an expanded spectrum of side effects of oncological therapies inevitably arises. The increasing use of immunotherapy…
